First Faculty of Medicine, Institute of Pharmacology, Charles University Prague, Albertov 4, 12800 Prague, Czech Republic.
Mediators Inflamm. 2013;2013:864319. doi: 10.1155/2013/864319. Epub 2013 May 20.
This paper reviews the impact of genetic variability of drug metabolizing enzymes, transporters, receptors, and pathways involved in chronic pain perception on the efficacy and safety of analgesics and other drugs used for chronic pain treatment. Several candidate genes have been identified in the literature, while there is usually only limited clinical evidence substantiating for the penetration of the testing for these candidate biomarkers into the clinical practice. Further, the pain-perception regulation and modulation are still not fully understood, and thus more complex knowledge of genetic and epigenetic background for analgesia will be needed prior to the clinical use of the candidate genetic biomarkers.
本文综述了参与慢性疼痛感知的药物代谢酶、转运体、受体和途径的遗传变异性对镇痛药和其他用于慢性疼痛治疗药物的疗效和安全性的影响。文献中已经鉴定出了几个候选基因，但通常只有有限的临床证据支持将这些候选生物标志物的检测纳入临床实践。此外，疼痛感知的调节机制仍不完全清楚，因此在候选遗传生物标志物的临床应用之前，还需要对镇痛的遗传和表观遗传背景有更复杂的了解。
